Similar articles

• Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease.

  Meco G, Bernardi S. Meco G, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jan 30;31(1):311-3. doi: 10.1016/j.pnpbp.2006.06.016. Epub 2006 Aug 17. Prog Neuropsychopharmacol Biol Psychiatry. 2007. PMID: 16919377
• Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study.

  Devos D, Dujardin K, Poirot I, Moreau C, Cottencin O, Thomas P, Destée A, Bordet R, Defebvre L. Devos D, et al. Mov Disord. 2008 Apr 30;23(6):850-7. doi: 10.1002/mds.21966. Mov Disord. 2008. PMID: 18311826 Clinical Trial.
• [Citalopram and desmethylcitalopram for psychiatric patients].

  Linnet K, Olesen OV. Linnet K, et al. Ugeskr Laeger. 1996 Aug 26;158(35):4920-3. Ugeskr Laeger. 1996. PMID: 8801700 Clinical Trial. Danish.
• [Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine].

  Montastruc JL, Schmitt L, Bagheri H. Montastruc JL, et al. Rev Neurol (Paris). 2003 Apr;159(4):441-3. Rev Neurol (Paris). 2003. PMID: 12773874 Review. French.
• Quality of life measurement in antidepressant trials. Is there an added value?

  De Fruyt J, Demyttenaere K. De Fruyt J, et al. Psychother Psychosom. 2009;78(4):212-9. doi: 10.1159/000214442. Epub 2009 Apr 28. Psychother Psychosom. 2009. PMID: 19401621 Review.